Spain's Almirall posts solid performance in 2009, setting basis for sustainable long-term growth

Spain's leading drugmaker Almirall reported full-year 2009 net sales of 925.5 million euros ($1.25 billion), up 2.5% on the previous year, on sustained growth of the international affiliates and acceleration of the partner activity.

Higher volumes provided nearly 3% of the growth, while price changes subtracted less than 1%. Euro sales represented most of net sales and the unfavorable impact of the UK sterling and the Mexican peso slightly hindered the positive trend in its evolution, the company said. Its top 10 products, representing 63% of net sales, were up 5.8% while the top six products grew at double digit (+10.7%).

Net income rises 11.3%